However, nothing is recommended regarding the possible cost benefits as a result of these findings. For example, in Greece, IV colistin formulations (each vial contains 75 mg of colistin messilate sodium, equal to 1 million International Units) cost €5.92 per vial; AS colistin formulations cost €2.93 per vial. Considering that the usual dose for IV therapy is 3 million International Units tid, and 1 million International Units tid for AS colistin as in the article by Tumbarello et al,1 we found that for a 10-day course of IV colistin monotherapy, the costs are €532.8, whereas for a 7-day combination of AS + IV therapy, the costs are €435.183. Thus, 7-day AS + IV therapy is less expensive as compared with 10-day IV monotherapy by €97.617 per patient. Also, median total variable daily ICU costs in our ICU are €573.18; the costs for intubated patients are €562.3 and €386.3 for nonintubated patients (data not published). Thus, a considerable cost benefit may occur as a result of fewer days under MV and shorter length of ICU stay.